BioMarin Pharmaceuticals Inc
$65.08
$0.35 (+0.54%)
$64.97Day Range$66.21
Key Statistics
Market Cap
$12.60B
Shares Outstanding
193.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 23, 1999
Round Lot
100
Locale
US
Trading Data
Day Open
$65.34
Day High
$66.21
Day Low
$64.97
Volume
1.38M
VWAP
$65.38
Prev Close
$64.73
Transactions
--
Acc. Volume
--
About BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
PHARMACEUTICAL PREPARATIONSSIC 28343,221 employees105 DIGITAL DRIVE, NOVATO, CA, 94949(415) 506-6700IPO Jul 23, 1999US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001048477
- Composite FIGI
- BBG000CZWZ05
- Share Class FIGI
- BBG001S76R05
- Ticker Root
- BMRN
- SIC Code
- 2834
About BioMarin Pharmaceuticals Inc (BMRN) Stock
BioMarin Pharmaceuticals Inc (BMRN) closed the 2026-09-17 session at $65.08, up 0.54% versus the previous close (+0.35). The stock opened at $65.34 and traded between $64.97 and $66.21 during that session. Session trading volume was 1.4M shares. The volume-weighted average price (VWAP) is $65.38.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
BioMarin Pharmaceuticals Inc has a market capitalization of $12.60 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BMRN is listed on the XNAS exchange. The company employs approximately 3,221 people. BioMarin Pharmaceuticals Inc is headquartered in NOVATO, CA. The recorded listing date is 1999-07-23.
On this page you can find market BMRN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.